One-sample molecular panel for scrub typhus, dengue, leptospirosis and typhoid
TL;DR Quadspot is a molecular test that checks one blood sample for the four infections behind most treatable fevers in Indian hospitals and gives an answer the same day. District and private hospitals buy the instrument and cartridges. It could work because a large share of fever patients leave without any diagnosis.
Fever with no obvious source is one of the most common reasons adults are admitted in India, and doctors often treat blind. At AIIMS Nagpur, 262 adults with such fevers were studied in 2024–2025. Scrub typhus and dengue led, but 42.7% never got a cause, and those undiagnosed patients accounted for a disproportionate share of deaths[1]. In Dehradun, only 7.32% of 38,869 suspected cases had an infection confirmed by blood tests[2].
Why so few answers? Each disease needs its own test today, often an antibody test that turns positive only days into the illness. Scrub typhus and leptospirosis need specific antibiotics, so a missed diagnosis costs lives.
What it does, in regulatory terms: an in vitro diagnostic for detecting pathogen DNA or RNA. It is a medical device under the Medical Devices Rules 2017 and needs CDSCO approval after a clinical performance evaluation before any sale[3]. It aids diagnosis, and the treating doctor decides.
Here's how it works. A technician loads one blood sample into a sealed cartridge. A bench instrument extracts and amplifies genetic material and reports which of the four targets is present, within about an hour. The panel comes from Indian data - scrub typhus, dengue, leptospirosis and enteric fever were the four leading confirmed causes in the Nagpur cohort[1]. Malaria already has cheap rapid tests, so it is left out of version one.
The seed proposed a CRISPR chip that detects many pathogens at once. Single-target CRISPR tests can reach 1–10 copies per microlitre in about an hour[4], but multiplexing in one readout is still hard. I kept the goal and left the chemistry open, so you use whichever amplification method passes evaluation first.
District hospitals and medical colleges buy through state procurement, while private hospitals and lab chains buy directly. The patient or the government scheme pays per test. I couldn't find a public price for a multiplex fever panel in India. One Indian chip-based PCR platform shows that Indian buyers adopt a portable molecular platform when a national programme backs it[5].
In September 2025 ICMR and CDSCO published standard performance-evaluation protocols for infectious-disease IVDs, which makes the approval path clearer[3]. Indian studies from 2025–2026 now document local fever causes and the gap left by antibody tests[1][2]. Portable PCR has been proven by Indian makers, and CRISPR detection is getting faster[4].
There's no public figure for India's spend on fever-cause testing. The narrow signal is that 42.7% of hospitalised fever patients went undiagnosed at one AIIMS[1]. Adjacent - a 2026 review of multiplex card testing across 16 studies found a pathogen in 43% of fever patients, though none were Indian[6].
That Indian platform runs 40+ single-target assays on a battery-powered PCR, including malaria[5]. A global diagnostics brand sells imported multiplex panels for respiratory, blood-culture and meningitis infections, but its panel list shows no fever panel[7]. Hospitals otherwise use separate antibody tests. I found no approved Indian panel for these four fevers, which is the gap Quadspot would fill.
| Difficulty | Hard (74/100) |
| Starting capital | ₹12–22 Cr |
| Time to launch | 30–42 months |
This is a regulated device company, plain and simple. You have to develop the chemistry and cartridge, run a clinical performance study across seasons and regions, and win CDSCO approval. Then you sell into slow state tenders against cheaper antibody kits, and you've got instruments to service in every district you win.
Yes. This is an in vitro diagnostic, so nothing ships without approval.
Building this outside India? The categories above usually have a local equivalent, so check with your own regulator.
Any software that reads results becomes part of the regulated device and must be validated with it. AI should never suggest a diagnosis or treatment, which stays with the doctor.
Want to work out the AI layer for Quadspot? Talk to Yash →
I'd only take this on with a team that has IVD development and CDSCO approval experience, plus patient capital. It is not a first-time founder's project. Before raising a large round, prove one thing - that a lab prototype detects all four targets in stored positive samples from an Indian hospital.
Plan for roughly ₹12–22 Cr, much of it for development, the instrument and clinical performance evaluation.
Yes. An IVD needs CDSCO approval after a clinical performance evaluation, and a manufacturing licence for its risk class.
Yes, where these fevers are common. You will need that country's IVD approval before selling. Plan the evaluation around the local fever mix, not India's.
The free Quadspot validation kit has the line-by-line capital breakdown, the effort scoring, the CDSCO approval checklist, a 14-day validation sprint with pass/fail targets, a 90-day launch plan, 10 interview questions for clinicians and lab heads, and 5 assumptions to test. Download the kit →
Thinking about building Quadspot or something close to it? The make-or-break work is a clinical performance study that holds up across seasons and regions, and that's the kind of plan I help founders put together. If you need a hand, you know where to find me. Talk to Yash →
For illustration only. Names are fictional and ideas hypothetical; sourced facts are real but may be out of date. Nothing here is legal, financial or professional advice, and Yash Khatri is not personally liable for any use of it. Read the full disclaimer.